These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 23146319

  • 1. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
    Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, Broutet N.
    BMC Med; 2012 Nov 13; 10():136. PubMed ID: 23146319
    [Abstract] [Full Text] [Related]

  • 2. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
    Quentin W, Terris-Prestholt F, Changalucha J, Soteli S, Edmunds WJ, Hutubessy R, Ross DA, Kapiga S, Hayes R, Watson-Jones D.
    BMC Med; 2012 Nov 13; 10():137. PubMed ID: 23148516
    [Abstract] [Full Text] [Related]

  • 3. Comprehensive approach to costing cervical cancer prevention and control: a case study in the United Republic of Tanzania using the Cervical Cancer Prevention and Control Costing (C4P) tool.
    Levin A, Yuma S, Swai E, Morgan W, Gauvreau CL, Broutet N, Yeung KHT, Hutubessy R.
    BMC Med; 2022 Nov 01; 20(1):384. PubMed ID: 36316680
    [Abstract] [Full Text] [Related]

  • 4. Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.
    Hsiao A, Struckmann V, Stephani V, Mmbando D, Changalucha J, Baisley K, Levin A, Morgan W, Hutubessy R, Watson-Jones D, Whitworth H, Quentin W.
    Vaccine; 2023 Jan 09; 41(2):372-379. PubMed ID: 36460537
    [Abstract] [Full Text] [Related]

  • 5. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects.
    Botwright S, Holroyd T, Nanda S, Bloem P, Griffiths UK, Sidibe A, Hutubessy RCW.
    PLoS One; 2017 Jan 09; 12(10):e0182663. PubMed ID: 29016596
    [Abstract] [Full Text] [Related]

  • 6. An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia.
    Simuyemba MC, Chama-Chiliba CM, Chompolola A, Sinyangwe A, Bchir A, Asiimwe G, Chibwesha C, Masiye F.
    BMC Infect Dis; 2024 Apr 02; 24(1):369. PubMed ID: 38565994
    [Abstract] [Full Text] [Related]

  • 7. National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.
    Mphuru A, Li AJ, Kyesi F, Mwengee W, Mazige F, Nshunju R, Shayo B, Giattas MR, Loharikar A, Lyimo D.
    Vaccine; 2022 Mar 31; 40 Suppl 1(Suppl 1):A2-A9. PubMed ID: 33962839
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.
    Vaccine; 2015 May 07; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [Abstract] [Full Text] [Related]

  • 9. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
    Levin A, Wang SA, Levin C, Tsu V, Hutubessy R.
    PLoS One; 2014 May 07; 9(6):e101114. PubMed ID: 24968002
    [Abstract] [Full Text] [Related]

  • 10. Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique.
    Alonso S, Cambaco O, Maússe Y, Matsinhe G, Macete E, Menéndez C, Sicuri E, Sevene E, Munguambe K.
    BMC Public Health; 2019 Aug 01; 19(1):1031. PubMed ID: 31370810
    [Abstract] [Full Text] [Related]

  • 11. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
    Ngabo F, Levin A, Wang SA, Gatera M, Rugambwa C, Kayonga C, Donnen P, Lepage P, Hutubessy R.
    Vaccine; 2015 Dec 16; 33(51):7357-7363. PubMed ID: 26519548
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA, Gow J, Alam K, Keramat SA, Hossain MG, Sultana M, Sarker AR, Islam SMS.
    Vaccine; 2020 Jan 10; 38(2):165-172. PubMed ID: 31668820
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M, Brisson M, Portnoy A, Hutubessy R.
    Lancet Glob Health; 2014 Jul 10; 2(7):e406-14. PubMed ID: 25103394
    [Abstract] [Full Text] [Related]

  • 14. Cost and operational context for national human papillomavirus (HPV) vaccine delivery in six low- and middle-income countries.
    Mvundura M, Slavkovsky R, Debellut F, Naddumba T, Bayeh A, Ndiaye C, Anena J, Vodicka E, Diop A, Gamage D, Musanabaganwa C, Tatkan G, Driwale A, Zelalem M, Badiane O, Ginige S, Hamilton E, Sibomana H, Lakew Y, Uwinkindi F, Dhufera A, Ampeire I, Kumar S, Lamontagne DS.
    Vaccine; 2023 Nov 30; 41(49):7435-7443. PubMed ID: 37949752
    [Abstract] [Full Text] [Related]

  • 15. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M, Laprise JF, Martin D, Jit M, Bénard É, Gingras G, Boily MC, Alary M, Baussano I, Hutubessy R, Brisson M.
    Lancet Infect Dis; 2021 Nov 30; 21(11):1598-1610. PubMed ID: 34245682
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM, de Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, Sartori AM, Clark AD, Resch S.
    Vaccine; 2015 May 07; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [Abstract] [Full Text] [Related]

  • 17. Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
    Brennan T, Hidle A, Doshi RH, An Q, Loharikar A, Casey R, Badiane O, Ndiaye A, Diallo A, Loko Roka J, Mejia N, Abimbola T.
    Vaccine; 2022 Mar 31; 40 Suppl 1(Suppl 1):A77-A84. PubMed ID: 34955325
    [Abstract] [Full Text] [Related]

  • 18. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 19. Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.
    Slavkovsky R, Callen E, Pecenka C, Mvundura M.
    Vaccine; 2024 Feb 27; 42(6):1200-1210. PubMed ID: 38302338
    [Abstract] [Full Text] [Related]

  • 20. Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts.
    Hidle A, Brennan T, Garon J, An Q, Loharikar A, Marembo J, Manangazira P, Mejia N, Abimbola T.
    Vaccine; 2022 Mar 31; 40 Suppl 1(Suppl 1):A67-A76. PubMed ID: 35181152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.